2023
1901. High Prevalence of Latent Tuberculosis Infection in a Malaysian Prison
Zhang L, Shenoi S, Kamarulzaman A, Dhaliwal S, Ahmad A, Altice F. 1901. High Prevalence of Latent Tuberculosis Infection in a Malaysian Prison. Open Forum Infectious Diseases 2023, 10: ofad500.1729. PMCID: PMC10677608, DOI: 10.1093/ofid/ofad500.1729.Peer-Reviewed Original ResearchLatent tuberculosis infectionPrevalence of LTBIRisk of LTBITB preventive therapyIndependent risk factorTuberculin skin testC-reactive proteinActive TBPreventive therapyTuberculosis infectionRisk factorsHigh prevalenceMultivariable logistic regressionOpioid use disorderRisk of hepatotoxicityChest X-rayDrug use historyPaucity of dataLTBI treatmentHCV infectionHepatitis CHepatitis BMedian ageBlood testsSkin test
2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes